VolitionRx presents early stage I solid cancer detection data for Capture-Seq at ESMO MAP conference
VNRX•Early clinical validation presented in London
VolitionRx announced early clinical validation results for its Capture-Seq liquid biopsy approach for detecting early-stage solid cancers.
The findings were presented at the ESMO MAP conference in London on Sept. 10, 2026.
Across multiple cohorts, the test distinguished cancer patients from healthy controls, supporting potential use in multi-cancer early detection.
Management also positioned the platform for minimal residual disease detection, a potential follow-on market alongside screening.
Volition estimated a $36 billion total addressable market spanning early cancer detection and MRD.
